Treats major depressive disorder (MDD). Sold as Pristiq. Every FDA application for this active ingredient: 1 branded and 11 generic. Boxed warning
As of Nov 22, 2026, FDA lists 12 applications for Desvenlafaxine succinate (sold as Pristiq), first approved Feb 29, 2008, with 3 new uses approved and 0 published complete response letters.
| Feb 29, 2008 | PristiqNDA 21992 · New molecular entity | PF PRISM CV | 32 | Marketed |
| Jun 29, 2015 | Desvenlafaxine SuccinateANDA 204003 | Alembic | 6 | Marketed |
| Jun 29, 2015 | Desvenlafaxine SuccinateANDA 204028 | Rubicon Research | 0 | Marketed |
| Jun 29, 2015 | Desvenlafaxine SuccinateANDA 204095 | PharmoBedient | 7 | Discontinued |
| Jun 29, 2015 | Desvenlafaxine SuccinateANDA 204172 | Lupin | 2 | Marketed |
| Feb 16, 2016 | Desvenlafaxine SuccinateANDA 204083 | Hikma Pharmaceuticals | 6 | Marketed |
| Jul 29, 2016 | Desvenlafaxine SuccinateANDA 204065 | Actavis Laboratories FL | 4 | Marketed |
| Oct 11, 2017 | Desvenlafaxine SuccinateANDA 204020 | Zydus Pharmaceuticals (USA) | 3 | Marketed |
| Oct 1, 2018 | Desvenlafaxine SuccinateANDA 210014 | Yichang Humanwell Pharmaceutical | 4 | Marketed |
| May 7, 2019 | Desvenlafaxine SuccinateANDA 204805 | Platinum | 2 | Marketed |
| Jan 15, 2025 | Desvenlafaxine SuccinateANDA 211427 | Macleods Pharmaceuticals | 0 | Marketed |
| Mar 10, 2026 | Desvenlafaxine SuccinateANDA 220460 | Yichang Humanwell Pharmaceutical | 0 | Marketed |
| Desvenlafaxine Succinate ER | Part D | $66.1M | +9% | 203,913 |
| Pristiq | Part D | $5.7M | −7% | 1,308 |
Of the 8 whose ending is known, 50% met their primary endpoint, 13% missed it and 38% stopped early.
| Modality Choice Before and After Failure for the Treatment of Painful Diabetic NeuropathyPainful Diabetic Neuropathy (PDN), Diabetic Nephropathies · University of Michigan | Phase 4 | Not yet recruiting | Aug 31, 2026 |
| Desvenlafaxine for Preventive Treatment of Frequent MigrainesMigraine · Tongji Hospital | Not applicable | Active, not recruiting | Feb 4, 2026 |
| The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes ZosterHerpes Zoster, Pain · Beijing Tiantan Hospital | Not applicable | Recruiting | Jan 23, 2026 |
| Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type HeadacheTension Type Headache · Tongji Hospital | Not applicable | Active, not recruiting | Jan 22, 2026 |
| The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With FibromyalgiaFibromyalgia, Pregabalin · Beijing Tiantan Hospital | Not applicable | Recruiting | Sep 12, 2025 |
| Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life DepressionDepression · University of Illinois Chicago | Phase 2 | Recruiting | Sep 19, 2024 |
| Implementation of Personalized Medicine for Optimal Drug Therapy in CancerNausea With Vomiting Chemotherapy-Induced, Depression, Reactive · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — | Recruiting | Apr 26, 2023 |
| Predictors of Cognitive Outcomes in Geriatric DepressionMajor Depressive Disorder, Neuroticism · David Steffens | Phase 4 | Active, not recruiting | Mar 10, 2022 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA